Answers are grounded in this paper and cite their sources.
Epigenetics encompasses a highly coordinated set of reversible mechanisms that regulate gene expression and function without altering the underlying DNA code. Emerging evidence indicates that dysregulation of epigenetic pathways contributes to the pathogenesis and progression of numerous central nervous system (CNS) disorders. This review summarizes the major epigenetic mechanisms implicated in neurological diseases, including histone acetylation and deacetylation, DNA methylation, microRNA-mediated regulation, and bromodomain and extraterminal domain (BET) protein signaling, and highlights emerging therapeutic strategies targeting these pathways. Epigenetic modulators, including histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) inhibitors, microRNA-based modulators, and BET inhibitors, can broadly influence transcriptional processes involved in neuroinflammation, neuronal survival, synaptic plasticity, and tissue repair. Although many of these approaches remain in the early stages of development, preclinical studies have demonstrated considerable potential to regulate pathological immune and inflammatory responses, promote neuroprotection, and enhance functional recovery following CNS injury and disease. Consequently, epigenetic-based therapies have emerged as promising disease-modifying strategies for a wide range of neurological disorders, including traumatic brain injury, stroke, epilepsy, neurodegenerative diseases, and chronic pain. We propose a unifying "neuroepigenetic therapy hypothesis" whereby precision targeting of reversible maladaptive epigenetic states can restore transcriptional homeostasis and shift treatment of neurological disorders from symptomatic control toward disease prevention, repair and disease-modification. A deeper understanding of the complex interplay among multiple transcriptional regulatory pathways may pave the way for precision neuroepigenetic therapies capable of preventing or mitigating chronic neurological disorders with improved efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: